Zurueck zur Suche

Reporte zur Charge UT7714AA

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

13Reporte angezeigt
1Todesfaelle
1Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
WI 3 NY 3 IL 2 ND 2 PA 2 MI 1

VAERS 2575072

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

kritisch
Staat
MI
Alter
73,0
Geschlecht
M
Eingang
03.02.2023
Impfdatum
01.10.2022
Beginn
13.01.2023
Tage bis Beginn
104,0
Dosis
N/A
Route/Site
- / -
Tod: ja Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: nein
Acute kidney injury Acute respiratory failure Autopsy Bacterial test negative Blood gases abnormal Brain natriuretic peptide increased Bronchoscopy abnormal COVID-19 Cardiac failure congestive Catheterisation cardiac Chest X-ray abnormal Computerised tomogram head abnormal Computerised tomogram thorax abnormal Cough Death Dyspnoea Echocardiogram abnormal Ejection fraction decreased

Symptomtext

Discharge Provider: Primary Care Physician at Discharge: MD Admission Date: 1/13/2023 PRESENTING PROBLEM: Lung abnormality [J98.4] Acute on chronic respiratory failure [J96.20] HOSPITAL COURSE: Patient was a 73 y.o. male who is s/p bilateral lung transplant 7/25/18 for IPF, complicated by MDS with pancytopenia, systolic and diastolic heart failure (currently compensated), CAD s/p CABG, then stent (7/2022), atrial flutter. He had COVID-19 infection 12/2022 which was not treated. He presented on 1/13/2023 with worsening respiratory symptoms (dyspnea, cough, wheezing, increased work of breathing, mild desaturation and 1 L drop in home spirometry), CT showing bilateral nodular pulmonary infiltrates. He underwent bronchoscopy 1/13/22 and was admitted to the lung transplant service for IV antibiotics and ID consultation. During bronchoscopy he had bloody secretions on initial bronch, hemoptysis and worsening infiltrates post bronchoscopy. Bronchoscopy with negative bacterial cutlures, empiric abx stopped 1/17. CXR worsening, ECHO obtained and EF down to 30%, previously 60%, with basal to mid anterolateral and apical segments severely hypokinetic, moderate MR. BNP over 37,000. Heart failure team were consulted. 1/18 RHC with Swan placement demonstrated biventricular failure- lasix and Milrinone gtt started per AHF team. 1/21 CT thorax with worsening perihilar infiltrates. Course further complicated by worsening AKI for which nephrology was consulted. Underwent RHC 1/30 on milrinone 0.1, with low filling pressures and normal CO. Milrinone was weaned off. He had worsening respiratory failure 2/1 and didn't tolerate attempts at BiPAP even with Precedex gtt. He had worsening mental status with ABG showing only hypoxemia. CT head without new acute abnormality. Ct thorax showed extensive bilateral ground-glass opacities, worse from prior study. GOC discussion with wife, daughter, and son at bedside with concern for need for intubation. They decided to transition to comfort care. At 1745, he passed away Per Lung Transplant team request, a limited chest autopsy was requested. Family consented. Date of Death: 2/2/23 Time of Death: 5:45 PM Preliminary Cause of Death: Acute respiratory failure

Weitere VAERSDATA-Felder
Praegender Schweregrund
Acute respiratory failure
Hospital-Tage
20,0
Labordaten
-
Aktuelle Erkrankungen
None
Vorgeschichte
IPF (idiopathic pulmonary fibrosis) OSA (obstructive sleep apnea) History of nicotine use History of psychiatric disorder Pulmonary fibrosis, s/p transplant 7/25/2018 Atial flutter CAD (coronary artery disease) Restless leg syndrome History of pulmonary embolism Other complications of lung transplant Steroid-induced diabetes Pseudoaneurysm History of atrial tachycardia Tachycardia Postoperative atrial fibrillation Hx of CABG Dyslipidemia Central Sleep Apnea on ASV Myocardial infarction Osteoporosis, unspecified osteoporosis type, unspecified pathological fracture presence Paroxysmal nocturnal dyspnea GERD with esophagitis Hiatal hernia BiPAP (biphasic positive airway pressure) ASV dependence Human metapneumovirus (hMPV) pneumonia Other specified anemias Primary insomnia Myelodysplastic syndrome Nonrheumatic aortic valve insufficiency Atypical atrial flutter Cardiomyopathy Pulmonary edema cardiac cause Acute respiratory failure Acute systolic congestive heart failure Ischemic cardiomyopathy Hyponatremia Moderate protein-calorie malnutrition Primary squamous cell carcinoma of left ear Anticoagulant long-term use Long term current use of anticoagulant therapy Actinic keratosis Arthritis Congenital pes planus, unspecified foot Elevated PSA History of cholecystectomy Status post lung transplantation Major depressive disorder, recurrent, moderate Polyp of colon Chronic alcoholism in remission Recurrent major depression in remission Sensorineural hearing loss, bilateral Spinal stenosis, lumbar region without neurogenic claudication Tobacco dependence in remission Unspecified cataract Unspecified disorder of refraction MDS (myelodysplastic syndrome) Lung abnormality Hemoptysis setting of abnormal CT scan demonstrating nodular opacities AKI on CKD 4 History of skin cancer Immunosuppressed status Multifocal lung consolidation Stress hyperglycemia Acute hypoxemic respiratory failure History of CVA (cerebrovascular accident)
Andere Medikamente
acetaminophen (TYLENOL) 500 MG tablet acyclovir (ZOVIRAX) 400 MG tablet apixaban (ELIQUIS) 5 MG tablet atorvastatin (LIPITOR) 40 MG tablet BMX compounded suspension buPROPion (WELLBUTRIN SR) 150 MG 12 hr tablet busPIRone (BUSPAR) 10 MG tabl
Allergien
Nsaids MoldOther PollenOther
Vorherige Impfungen
-

VAERS 2482810

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

schwer
Staat
IL
Alter
86,0
Geschlecht
M
Eingang
19.10.2022
Impfdatum
08.10.2022
Beginn
08.10.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
SYR / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Contusion Infection Thrombosis

Symptomtext

Patient's wife came in to the pharmacy and showed pictures of patient's arm which showed a large bruise from shoulder to elbow. Patient's wife is worried that it is a blood clot or an infection. Patient's wife states patient went to immediate care a few days ago and they did not do anything for treatment, and then the following day patient went to primary care physician and they did not do anything for treatment there as well. Both the photographs and the response from the doctor's office is that the reaction is likely a bruise from the blood thinners a patient is taking (warfarin and clopidogrel) and the bruise will likely heal on its own and no treatment is necessary.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Thrombosis
Hospital-Tage
-
Labordaten
Patient went to immediate care around 10/15/22 and went to primary care physician on 10/17/22 and no treatment was necessary.
Aktuelle Erkrankungen
Unknown
Vorgeschichte
Blood thinners
Andere Medikamente
warfarin, amlodipine, atorvastatin, hydrochlorothiazide, isosorbide, clopidogrel, tamsulosin, allopurinol,
Allergien
Penicillin
Vorherige Impfungen
-

VAERS 2713568

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

moderat
Staat
ND
Alter
78,0
Geschlecht
F
Eingang
13.11.2023
Impfdatum
12.09.2023
Beginn
12.09.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Arthralgia Injected limb mobility decreased Injection site pain Injection site paraesthesia Pain Pain in extremity

Symptomtext

Patient contacted clinic the day following immunization to report that her arm was "really, really sore" indicating that she had never experienced this kind of pain before. Symptomatic therapy with warm packs alternating with ice as well as acetaminophen to use as needed discussed. Patient later noted that one hour after the shot she started to feel tingling in her left arm (site of injection). Within a few hours there was notable pain radiating from elbow to shoulder. There was no swelling, red streaks, or warmth. Described pain October 9 as a "band with one intense point." No changes in mobility, but noted discomfort carrying items weighing less than 5 pounds and with lifting arm overhead as well as repositioning in bed. Seen in clinic 10/12/2023 with pain to left shoulder superior medial area or deltoid. Decreased ROM to 90 degrees. No other abnormalities noted on exam. Prescribed Naproxen 220 mg bid and alternate with acetaminophen as well as initiating physical therapy. After 4th session of physical therapy feels pain may now be improving slightly.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injected limb mobility decreased
Hospital-Tage
-
Labordaten
As noted in Item 18
Aktuelle Erkrankungen
No recent illness
Vorgeschichte
Osteopenia; Hypercholesterolemia; Iron Deficiency Anemia; Rosacea; oropharyngeal dysphagia; environmental allergies; situational anxiety
Andere Medikamente
Metronidazole topical gel; Lexapro; Rosuvastatin; Loratadine; azelastine; ferrous sulfate; calcium carbonate-Vitamin D; Cinnamon; Omega-3 Fatty Acid; Multivitamin; carboxymethylcellul-Glycerin Solution to eyes; flaxseed capsules; magnesium
Allergien
No Known Allergies
Vorherige Impfungen
-

VAERS 2492286

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

moderat
Staat
PA
Alter
83,0
Geschlecht
F
Eingang
28.10.2022
Impfdatum
26.10.2022
Beginn
27.10.2022
Tage bis Beginn
1,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein
Asthenia Dehydration Fall Pyrexia

Symptomtext

fever dehydration weakness fell out of bed

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dehydration
Hospital-Tage
-
Labordaten
received fluids in ER
Aktuelle Erkrankungen
None
Vorgeschichte
Pre-Existing: DM, HTN, Cholesterol Allergies: Lisinopril, Codeine, Opiates
Andere Medikamente
Amitriptyline Lipitor Losartan
Allergien
-
Vorherige Impfungen
-

VAERS 2608325

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

mild
Staat
ND
Alter
84,0
Geschlecht
F
Eingang
03.04.2023
Impfdatum
30.09.2022
Beginn
30.09.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site pain Pain Pain in extremity

Symptomtext

Right arm/shoulder pain when pulling up pants, taking off bra or tucking in shirt. No redness, No swelling, No nodules, Not in the shoulder its right where they shot was given.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pain
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
none
Vorgeschichte
none Reported
Andere Medikamente
Unknown
Allergien
none
Vorherige Impfungen
-

VAERS 2470751

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

mild
Staat
WI
Alter
77,0
Geschlecht
F
Eingang
06.10.2022
Impfdatum
04.10.2022
Beginn
06.10.2022
Tage bis Beginn
2,0
Dosis
N/A
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Diarrhoea Nausea Vomiting

Symptomtext

Nausea, vomiting, diarrhea

Weitere VAERSDATA-Felder
Praegender Schweregrund
Diarrhoea
Hospital-Tage
-
Labordaten
n/a
Aktuelle Erkrankungen
n/a
Vorgeschichte
n/a
Andere Medikamente
Tylenol 1g
Allergien
n/a
Vorherige Impfungen
-

VAERS 2512798

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

gering
Staat
WI
Alter
80,0
Geschlecht
F
Eingang
21.11.2022
Impfdatum
19.11.2022
Beginn
19.11.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered

Symptomtext

Client received additional dose of Flu Vaccine on 11/19/2022, client had received previous dose of flu vaccine on 10/18/22 .

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
NKDA
Vorherige Impfungen
-

VAERS 2507404

SEQIRUS, INC. · INFLUENZA (SEASONAL) (AFLURIA QUADRIVALENT) · Charge UT7714AA

gering
Staat
NY
Alter
64,0
Geschlecht
M
Eingang
14.11.2022
Impfdatum
03.11.2022
Beginn
01.11.2022
Tage bis Beginn
-
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Incorrect dose administered Product administered to patient of inappropriate age

Symptomtext

Dose error Administered high dose and person under 65 years

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
n/a
Vorgeschichte
n/a
Andere Medikamente
n/a
Allergien
n/a
Vorherige Impfungen
-

VAERS 2495189

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

gering
Staat
IL
Alter
79,0
Geschlecht
F
Eingang
01.11.2022
Impfdatum
19.10.2022
Beginn
19.10.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Wrong product administered

Symptomtext

No adverse events occurred due to error*- patient was inadvertently given flu vaccine instead of COVID booster. Patient aware. Check on with no adverse side effects from error. Med sheet colors changed to distinguish and avoid future errors.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2490931

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

gering
Staat
NY
Alter
-
Geschlecht
U
Eingang
27.10.2022
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error No adverse event Poor quality product administered Product storage error

Symptomtext

30 patients received FLUZONE HIGH DOSE QIV after the vaccine experienced a temperature excursion with no reported adverse event; vaccine experienced a temperature excursion that was not covered by the extended stability data with no reported adverse event; Initial information on 19-Oct-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case is linked to case 2022SA435111(CLUSTER). This case involves 30 unknown age and unknown gender patients who received fluzone high dose qiv after the vaccine experienced a temperature excursion that was not covered by the extended stability data with no reported adverse event while receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE experienced a temperature excursion that was not covered by the extended stability data with no reported adverse event (product storage error). On an unknown date, the patients received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (formulation, strength, dose, route not reported; lot UT7714AA) for prophylactic vaccination. On an unknown date, the 30 patients received fluzone high dose qiv after the vaccine experienced a temperature excursion with no reported adverse event (poor quality product administered). Action taken was not applicable. At time of reporting, the outcome was Unknown for both the events. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2488432

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

gering
Staat
WI
Alter
63,0
Geschlecht
F
Eingang
25.10.2022
Impfdatum
21.10.2022
Beginn
01.10.2022
Tage bis Beginn
-
Dosis
N/A
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Product administered to patient of inappropriate age

Symptomtext

Patient given high dose influenza vaccine and did not meet the 65 year requirement. This was missed during screening process at mass vaccination clinic. No adverse reactions occurred, but wrong dose was given.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
unknown
Vorgeschichte
unknown
Andere Medikamente
unknown
Allergien
none
Vorherige Impfungen
-

VAERS 2475159

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

gering
Staat
PA
Alter
60,0
Geschlecht
F
Eingang
12.10.2022
Impfdatum
06.10.2022
Beginn
06.10.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product administered to patient of inappropriate age

Symptomtext

fluzone high-dose quadrivalent being administered to a patient under 65 years of age (with no reported adverse event); Initial information was received on 06-Oct-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 60 years old female patient to whom fluzone high-dose quadrivalent being administered to a patient under 65 years of age (with no reported adverse event). The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 06-Oct-2022, the patient received 0.7 ml of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (lot-UT7714AA and expiry 30-06-23) via intramuscular route in the left deltoid for immunization. On 06-OCT-2022 the patient developed a non-serious fluzone high-dose quadrivalent being administered to a patient under 65 years of age (with no reported adverse event) (product administered to patient of inappropriate age) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. Action taken:not applicable. At time of reporting, the outcome was Unknown for the event fluzone high-dose quadrivalent being administered to a patient under 65 years of age (with no reported adverse event). This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2474471

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UT7714AA

gering
Staat
NY
Alter
66,0
Geschlecht
M
Eingang
11.10.2022
Impfdatum
28.09.2022
Beginn
28.09.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Atrial fibrillation Heart rate increased

Symptomtext

heart rate increased to 150 and continued to remian this high rate throughout the night; was in afib; Initial information received on 05-Oct-2022 regarding an unsolicited valid serious case received from a consumer/non-hcp. This case involves a 66 years old male patient who was in afib (atrial fibrillation), after receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The patient's past medical treatment(s), vaccination(s) and family history were not provided. The patient had no medical history, concomitant disease or risk factor. On 28-Sep-2022 at 02:00 pm, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE , suspension for injection in prefilled syringe, (lot: UT7714AA ; expiry date: not reported) via intramuscular route for flu vaccination (influenza vaccination). On the same day at 3:30pm following the administration, heartrate increased to 150 and continued to remain at this high rate throughout the night (heart rate increased) and went into afib (atrial fibrillation). These events were assessed as medically significant. The patient went to my local emergent care in the morning, where they gave me last dose aspirin and intravenous (iv) diltiazim. Heart rate decreased, but was still in afib. The higher heart rate and afib resolved on evening of 30-Sep-2022. Patient did not experience any additional symptoms/events. There were no lab data/results available Relevant laboratory test results included: Heart rate - On 28-Sep-2022: [heartrate increased to 150] Action taken: not applicable. Corrective treatment: ACETYLSALICYLIC ACID (ASPIRIN [ACETYLSALICYLIC ACID]) and DILTIAZEM (DILTIAZEM) for atrial fibrillation and its symptom. Outcome: Recovered / Resolved on 30-Sep-2022 for the event of atrial fibrillation and its symptom.; Sender's Comments: Sanofi company comment date 10-Oct-2022: This case involves a 66 years old male patient who experienced atrial fibrillation after receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The time to onset (same day) is suggestive of a relationship with the vaccine. However, a detailed clinical course was not provided. Limited information was also provided regarding circumstances leading to and patient's health status directly preceding the reported events. Further information is needed to fully assess the case.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Atrial fibrillation
Hospital-Tage
-
Labordaten
Test Date: 20220928; Test Name: heart rate; Result Unstructured Data: heartrate increased to 150
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-